Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDividends Paid - CommonDividends Paid - CommonExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares RepurchasedShort-Term Debt issuancesShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Conmed (CNMD) Cash from Financing Activities (2016 - 2026)

Conmed filings provide 17 years of Cash from Financing Activities readings, the most recent being -$22.6 million for Q1 2026.

  • On a quarterly basis, Cash from Financing Activities rose 20.58% to -$22.6 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$130.0 million, a 19.96% increase, with the full-year FY2025 number at -$135.8 million, up 10.05% from a year prior.
  • Cash from Financing Activities hit -$22.6 million in Q1 2026 for Conmed, up from -$37.4 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $159.1 million in Q2 2022 to a low of -$58.8 million in Q4 2023.
  • Median Cash from Financing Activities over the past 5 years was -$26.5 million (2025), compared with a mean of -$11.5 million.
  • Biggest five-year swings in Cash from Financing Activities: surged 820.17% in 2022 and later plummeted 610.34% in 2023.
  • Conmed's Cash from Financing Activities stood at $11.5 million in 2022, then plummeted by 610.34% to -$58.8 million in 2023, then increased by 13.1% to -$51.1 million in 2024, then increased by 26.83% to -$37.4 million in 2025, then skyrocketed by 39.65% to -$22.6 million in 2026.
  • The last three reported values for Cash from Financing Activities were -$22.6 million (Q1 2026), -$37.4 million (Q4 2025), and -$43.5 million (Q3 2025) per Business Quant data.